ESR1 and breast cancer: The same group observed that in another model of carcinoma, i.e., the mouse mammary tumor MMTV-neu transgenic model, CDDO-Me plus the rexinoid LG100268 significantly delayed the onset of estrogen receptor (ER)-negative mammary tumors if compared to controls [100].